Willasch, Andre Manfred and Horgan, Claire and Peters, Christina and Balduzzi, Adriana and Dalle, Jean-Hugues and Zecca, Marco and Al-Ahmari, Ali and Locatelli, Franco and Renard, Cecile and Mirci-Danicar, Oana and Jubert, Charlotte and Faraci, Maura and Gossetis, Evgenios and Michel, Gerard and Benedetti, Edoardo and Mitchell, Richard and Fagioli, Franca and Formankova, Renata and Lucchini, Giovanna and Rao, Kanchan and Biffi, Alessandra and Rialland, Fanny and Toren, Amos and Ansari, Marc and Dalissier, Arnaud and Corbacioglu, Selim and Kleinschmidt, Katharina and Bader, Peter and Ngoya, Maud and Galimard, Jacques-Emmanuel and Kalwak, Krzysztof (2026) Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission: a multicenter study from the EBMT PDWP. BONE MARROW TRANSPLANTATION, 61. pp. 67-74. ISSN 0268-3369, 1476-5365
Full text not available from this repository. (Request a copy)Abstract
Allogeneic haematopoietic stem cell transplantation (HSCT) is an essential treatment component for high-risk paediatric acute myeloid leukaemia (AML), but the choice of the optimal conditioning regimen remains controversial. We compared outcomes of two widely used myeloablative regimens, BuCy (Busulfan, Cyclophosphamide) versus BuCyMel (Busulfan, Cyclophosphamide, Melphalan) in children aged under 2 years undergoing HSCT in 1st complete remission (CR1). This international, registry-based study was conducted by the Paediatric Diseases Working Party (PDWP) of the European Society for Blood and Marrow Transplant (EBMT) and included patients transplanted from 2000-2022. 335 patients, transplanted across 98 centres, were included, 185 (55.2%) patients received BuCy and 150 patients (44.8%) received BuCyMel. BuCyMel was associated with significantly better leukaemia-free survival (LFS) (4 y: 74.8% vs 58.8%, HR 0.52 (95%CI: 0.33-0.82), p = 0.004) and overall survival (OS) (4 y: 77.9% vs 66.2%, HR 0.55 (95%CI: 0.33-0.91), p = 0.02) compared with BuCy, and significantly lower relapse incidence (4 y: 18.1% BuCyMel vs 31.5% BuCy, HR 0.50 (95%CI 0.29-0.87), p = 0.01). Four-year non-relapse mortality (NRM) did not differ between groups. Our results suggest that BuCyMel is a better conditioning regimen compared with BuCy in children aged under 2 years undergoing HSCT for CR1 AML.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | HEMATOPOIETIC-CELL TRANSPLANTATION; BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; CONDITIONING REGIMEN; INITIAL THERAPY; CHILDREN; BUSULFAN; SURVIVAL; AML; CYCLOPHOSPHAMIDE |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 15 Oct 2026 06:58 |
| Last Modified: | 15 Oct 2026 06:58 |
| URI: | https://pred.uni-regensburg.de/id/eprint/68031 |
Actions (login required)
![]() |
View Item |

